Can You Get Retatrutide Legally? Clinical Trials, Early Access and When Reta Might Be Approved

The short answer

Retatrutide is an experimental weekly shot that works on three hormone receptors (GLP-1, GIP and glucagon), compared with one for Wegovy and two for Zepbound. It is not approved anywhere, and it can't be prescribed and filled at a pharmacy the way Zepbound or Wegovy can.

As Dr. Weiner put it on Episode 89 of The Pound of Cure Weight Loss Podcast: "There's only two ways that you can receive reta legally right now." The first is a clinical trial. The second is a narrow expanded access program. Everything else is the black market.

Route 1: Join a clinical trial

Lilly is still studying retatrutide, and clinical trials are the main legal way to take it. In a trial you get a known, pure product, and a research team watches your dose, side effects and heart rate the whole time.

The catch is that spots are limited and the entry rules are strict. "They're pretty restrictive and all clinical trials have very strict criteria," Dr. Weiner said in the episode. Studies are listed on ClinicalTrials.gov, where each one spells out who can join. Your doctor can help you read the criteria and decide whether a trial is worth pursuing.

Route 2: Single-patient expanded access

Lilly also runs a pre-approval expanded access program for retatrutide (listed on ClinicalTrials.gov as NCT07629401). It is for one patient at a time, requested by that patient's doctor, and it is limited to people who meet all of these:

• Age 18 or older
• A BMI of 35 or higher, even after taking and tolerating the highest available dose of an approved weight loss medicine
• At least two serious or life-threatening obesity-related complications that are being treated
• Unable to join an ongoing retatrutide trial

That leaves out most people. Dr. Weiner described this route on the podcast as "very difficult, if not impossible," so it isn't something to count on.

When might retatrutide be approved?

Lilly has not filed for FDA approval yet. It moved its planned filing from the end of 2026 to the first quarter of 2027 so it could finish its manufacturing and quality-control data. Lilly is also in a legal dispute with the FDA over whether retatrutide counts as a biologic, which could affect how it's reviewed.

Put together, approval is likely not before late 2027. That's an outside estimate, not a promise from Lilly, and no one can give you a real approval date yet. The practical takeaway: plan around the medicines available now, because reta is a year or more away.

Why online reta is black market, not compounded

Compounding pharmacies were allowed to make copies of semaglutide and tirzepatide during the shortages. Retatrutide is different. Because it isn't approved and isn't part of any FDA-approved drug, it can't legally be compounded or sold, so every vial sold online today is black market.

The FDA has sent warning letters to sellers and recommends that consumers not buy these products, which are of unknown quality. Lilly has sued companies that claim to sell retatrutide. America's Poison Centers logged 862 exposures to retatrutide from July through September 2026, up from 249 in the first three months of the year, CBS News reported. An exposure is a call about contact with the product, not necessarily a poisoning.

The FDA has also received reports of two deaths after taking products sold as retatrutide. Those reports don't prove the drug caused the deaths. The point is that you can't know what's in the vial, and no one is watching you while you take it. We cover this in more detail in Is reta safe?.

If you've taken a product sold as retatrutide and feel unwell, call Poison Help at 1-800-222-1222 or your doctor, and keep the vial. For chest pain, fainting or trouble breathing, call 911.

Even the real thing needs a doctor watching

In the trials, people on the highest retatrutide dose lost an average of 25% of their body weight at 80 weeks, counting everyone who started, including people who stopped. That's impressive, but it's about 4 percentage points more than tirzepatide's average at its top dose in a separate trial, not a world apart.

Even under medical supervision, the side effects are real: nausea in about 4 in 10 people on the top dose, about 1 in 9 people on the top dose stopping because of side effects in the main trial, a skin burning sensation called dysesthesia, and a higher heart rate. The long-term heart outcomes trial is still running. A medicine this strong needs a doctor watching dose increases, side effects and heart rate, which is exactly what a black market vial doesn't come with.

What to do while you wait

Most people asking about reta aren't really looking for reta. They're looking for something that works better than what they're on. Here's where to start:

1. Check whether your response is really poor. Compare your weight loss with the clinical trials for your medication, dose and time on treatment with our free GLP-1 check.
2. Talk with your doctor about your dose. A stall doesn't always mean the medicine has stopped working.
3. Ask about switching. Some people do better on semaglutide and others on tirzepatide, so a poor response to one doesn't mean every GLP-1 will fail.
4. Consider surgery. For some people, weight loss surgery is the right next step.

You can learn more about how we approach medication in our GLP-1 medications overview.